×

Dr. Satheesh C T

Dr. Satheesh C T

Dr. Satheesh C T

QualificationMBBS, MD (Paediatrics), DM (Medical Oncology), ESMO (European Society of Medical Oncology), FRCP (Edin)

SpecialitiesMedical Oncology / cancer medicine

Locations HCG Cancer Center - KR BLRHCG Cancer Center - DR BLR
Book an Appointment

Area of Expertise

  • Dr. Satheesh is a consultant – medical and haemato oncology and the director of clinical trials at HCG Cancer Centre, Bengaluru.
  • Dr. Satheesh’s key areas of experience include the treatment of various solid and haematological cancers with conventional, high-dose chemotherapy, targeted chemotherapy and immunotherapy.
  • His other areas of specialisation include paediatric malignancies, lymphomas, and gynaecological cancers, along with breast and lung cancers and cancer genomics.   
  • Dr. Satheesh is well versed in delicate procedures like bone marrow aspiration and biopsy, central line insertion, lumbar puncture and autologous stem cell transplantation.
  • He also has vast experience in intraperitoneal chemotherapy, personalised medicine based on genomics and palliative care.
  • Dr. Satheesh has so far handled more than 20000 cases. 

Research & Publications

  • FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumour Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties. Canc Therapy & Oncol Int J. 2021; 19(1): 556003.
  • Landscape of clinically actionable mutations in breast cancer 'A cohort study'. Transl Oncol. 2021 Jan;14(1):100877.
  • Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies. J Cancer Res Ther. 2021 Jan-Mar;17(1):114-121.
  • The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments. Mol Clin Oncol. 2019 Apr;10(4):469-475.
  • Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience. Annals of Oncology 27 (Supplement 6): vi455–vi461, 2016.
  • Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine.
  • Journal of Thoracic Oncology, Vol. 12, Issue 1, S974–S975: January 2017.
  • Indian experience of Lenvatinib in radio-iodine refractory differentiated thyroid cancer.
  • May 2018 Journal of Clinical Oncology 36(15_suppl) :e18107-e18107.
  • Landscape of clinically actionable mutations in breast cancer ‘A cohort study’. January 2021, Translational Oncology 14(1):100877.  

Medical Breakthrough

  • Dr. Satheesh is involved in various clinical trials on cancer research and has a more than 50 number of national and international publications to his credit.                               

Awards & Accolades

  • He also received extensive training in the essentials of palliative care and clinical placement in palliative care from IAPC.                             

Other Doctors